AAPS will host the 2022 National Biotechnology Conference in-person this May 9-12, 2022 at the Anaheim Marriott.
The overarching theme for this year’s NBC is the concept of understanding how we can let science and innovation lead us in accelerating and improving our biotechnology drug development processes. The three tracks each explore different settings that create paradigm-challenging circumstances to the “business as usual” of biotechnology drug development because they do not fit into established processes. How can we get better and more effective in evolving existing paradigms and increase speed to patient?
Opening Plenary with Ozan Varol
Monday, May 9, 2022
3:00 PM – 4:30 PM
Ozan Varol
Rocket Scientist turned Award-winning Professor and #1 Bestselling Author
Ozan Varol is a rocket scientist turned award-winning professor and #1 bestselling author of Think Like a Rocket Scientist: Simple Strategies You Can Use to Make Giant Leaps in Work and Life. He is one of the world’s foremost experts in creativity, innovation, and critical thinking. He helps industry-leading organizations reimagine the status quo with moonshot thinking.
Closing Plenary with Dr. Laura Carter
Thursday, May 12, 2022
3:45 PM – 5:00 PM
Laura Carter, Ph.D.
Chief Scientific Officer, GossamerBio
Laura Carter, Ph.D. has served as our Chief Scientific Officer since April 2021, previously having served as our Senior Vice President, Research & Translational Biology since joining Gossamer in March 2019. Dr. Carter has over 20 years of industry experience spanning target identification and validation activities through Phase 2 clinical trials in multiple therapeutic areas. Prior to joining Gossamer, she was Senior Vice President, Biology at Lycera Corporation, where she led the development of several immunology and immuno-oncology clinical product candidates. Before joining Lycera, she was a scientific director in the respiratory, inflammation and autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. Prior to MedImmune, she was a senior research investigator in the inflammation biology and translational science department at Array Biopharma. She started her career in industry at Wyeth, where, among other accomplishments, her basic science studies were critical in identifying and characterizing the negative regulatory role of PD-1:PD-L interactions on T cell function in vitro and in vivo.